BridGene Biosciences Secures $28 Million Series B+ to Propel Next-Gen Oncology and Autoimmune Therapeutics
BridGene Biosciences, a San Jose–based biotech innovator focused on tackling traditionally “undruggable” molecular targets, has raised $28 million in a Series B+ funding round led by Bayland Capital. This capital injection will accelerate clinical advancement of BridGene’s lead candidate, BGC-515—a covalent TEAD inhibitor aimed at solid tumors—and fuel expansion of its proprietary IMTAC™ chemoproteomic platform…
